Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Set To Become New Center Of Pharma: PricewaterhouseCoopers Report

This article was originally published in PharmAsia News

Executive Summary

Asia is poised to become the new center of the global pharmaceutical industry, according to a PricewaterhouseCoopers report, with China and India set to be the largest beneficiaries

You may also be interested in...



Ranbaxy/GSK Partnership Yields First Drug Candidate

Ranbaxy will develop a respiratory disease candidate through proof of concept under an expanded discovery agreement inked with GSK in February.

Merck “Scouting” For Opportunities In China, India, Exec Says

Firm is looking to increase deal flow in developing markets, company exec tells BIO Asia conference in Tokyo.

Singapore Biomedical Sciences Group Director Yeoh Keat Chuan: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Singapore government official talks about the country’s R&D strengths and how it is handling increased competition from other Asian nations.

Related Content

UsernamePublicRestriction

Register

SC066226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel